Biotech Values

[TheFinalCD]

$VKTX I believe it is reasonable to expect the results of the Phase 2 trial for oral VK 2835 to be presented by the end of Q2 2025. This estimate is based on the previous clinical development timelines for QW VK2745.

Briefly, it took 15 months from P1 initiation on Jan 10 2022… pic.twitter.com/8H56dcNBuy

— Noumena Analysis (@GilaMonstrum) January 10, 2025